Bao Tran Vuong et Chloé Delépine de l'équipe Venteclef discovered how Immunometabolic endotypes define distinct clinical trajectories in type 2 diabetes
Immunometabolic endotypes define distinct clinical trajectories in type 2 diabetes
Cell Metabolism – August, 2026
The IMMEDIAB team, headed by Nicolas Venteclef, in the context of the European project Intercept-T2D, defined four novels immune endotypes in individuals with type 2 diabetes (T2D). In this study, published in Cell Metabolism, the team investigated the characteristics of these four immunotypes, the link between their inflammatory profile and cardiovascular, renal and mortality risks, as well as potential strategies to reshape the inflammatory endotypes.
Using unsupervised clustering across three European and independent cohorts, the authors identified four stable and reproductible immune endotypes: severe inflammatory diabetes (SIND), mild inflammatory diabetes (MIND), lymphocyte-rich diabetes (LYRD), and lymphocyte-deficient diabetes (LYDD). Analyses these endotypes shown that SIND and LYDD, the two pro-inflammatory endotypes, are associated with higher cardiovascular, renal and mortality risks. Furthermore, the SIND endotype is characterized by an inflammatory monocyte program and altered lymphocyte states. Still, the authors demonstrated that IL-1β antagonism and metabolic surgery can attenuate the inflammatory profile of SIND.
Together, these findings provide new insights into immune cell composition and function in T2D progression and open new perspectives for the integration of immune endotyping into diabetology, risk stratification, and targeted therapeutic strategies.